血小板抑制剂停药时机与冠脉术后结局的个体患者数据荟萃分析
该研究基于7项观察性研究、4837例患者的个体数据,评估P2Y12抑制剂术前停药时程与孤立体外循环CABG术后严重出血及缺血事件的关联。校正EuroSCORE II和体外循环时间后,符合指南的停药与氯吡格雷患者BARC-4出血风险降低相关(校正OR 0.48,95%CI 0.28-0.81,P=0.006),替格瑞洛呈下降趋势(校正OR 0.48,95%CI 0.22-1.05,P=0.067)。符合指南停药未显著增加30天死亡或术后缺血事件风险。
要点
- 符合指南停药与氯吡格雷患者BARC-4出血风险降低相关,替格瑞洛呈下降趋势。
- 符合指南停药未显著增加30天死亡风险(氯吡格雷校正OR 0.70,替格瑞洛校正OR 0.89)。
- BARC-4出血与30天死亡风险升高相关(校正OR 4.76,95%CI 2.67-8.47,P<0.001)。
核心结论
- 校正EuroSCORE II和体外循环时间后,符合指南的术前替格瑞洛和氯吡格雷停药与BARC-4出血风险降低约50%相关,但未增加30天死亡或术后缺血事件风险。
研究设计与样本
- 个体患者数据荟萃分析,检索PUBMED、Embase等数据库2013年至2024年3月,纳入7项观察性研究共4837例患者,采用两阶段IPD-MA分析。
主要发现
- BARC-4出血、30天死亡和术后缺血事件发生率分别为20%、2.6%和5.2%。
- 校正后符合指南停药与氯吡格雷患者BARC-4出血风险降低相关(校正OR 0.48,95%CI 0.28-0.81,P=0.006),替格瑞洛呈下降趋势(校正OR 0.48,95%CI 0.22-1.05,P=0.067)。
- 符合指南停药与30天死亡风险无显著关联(氯吡格雷校正OR 0.70,95%CI 0.30-1.61;替格瑞洛校正OR 0.89,95%CI 0.37-2.18)。
- 符合指南停药与氯吡格雷患者术后缺血事件风险降低相关(校正OR 0.50,95%CI 0.30-0.82),替格瑞洛无显著关联(校正OR 0.78,95%CI 0.45-1.37)。
- BARC-4出血与30天死亡风险升高相关(校正OR 4.76,95%CI 2.67-8.47,P<0.001)。
关键数值与推荐
- BARC-4出血定义为以下任一:围术期颅内出血、因出血再次手术、输注≥5单位红细胞、胸管引流量≥2 L。
- 术后缺血事件按Academic Research Consortium 2共识文件定义。
临床怎么用
- 对于择期孤立体外循环CABG患者,按指南推荐时程停用氯吡格雷或替格瑞洛与降低BARC-4出血风险相关,且未增加30天死亡或术后缺血事件风险。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the association between guideline-conforming as compared to shorter than recommended withdrawal period of P2Y12 receptor inhibitors prior to isolated on-pump coronary artery bypass grafting (CABG) and the incidence of severe bleeding and ischaemic events. Randomized controlled trials are lacking in this field. METHODS: We searched PUBMED, Embase and other suitable databases for studies including patients on P2Y12 receptor inhibitors undergoing isolated CABG and reporting bleeding and postoperative ischaemic events from 2013 to March 2024. The primary outcome was incidence of Bleeding Academic Research Consortium type 4 (BARC-4) bleeding defined as any of the following: perioperative intracranial bleeding, reoperation for bleeding, transfusion of ≥5 units of red blood cells, chest tube output of ≥2 l. The secondary outcome was postoperative ischaemic events according to the Academic Research Consortium 2 Consensus Document. Patient-level data provided by each observational trial were synthesized into a single dataset and analysed using a 2-stage IPD-MA. RESULTS: Individual data of 4837 patients from 7 observational studies were synthesized. BARC-4 bleeding, 30-day mortality and postoperative ischaemic events occurred in 20%, 2.6% and 5.2% of patients. After adjusting for EuroSCORE II and cardiopulmonary bypass time, guideline-conforming withdrawal was associated with decreased BARC-4 bleeding risk in patients on clopidogrel [adjusted odds ratio (OR) 0.48; 95% confidence intervals (CI) 0.28-0.81; P = 0.006] and a trend towards decreased risk in patients on ticagrelor (adjusted OR 0.48; 95% CI 0.22-1.05; P = 0.067). Guideline-conforming withdrawal was not significantly associated with 30-day mortality risk (clopidogrel: adjusted OR 0.70; 95% CI 0.30-1.61; ticagrelor: adjusted OR 0.89; 95% CI 0.37-2.18) but with decreased risk of postoperative ischaemic events in patients on clopidogrel (clopidogrel: adjusted OR 0.50; 95% CI 0.30-0.82; ticagrelor: adjusted OR 0.78; 95% CI 0.45-1.37). BARC-4 bleeding was associated with 30-day mortality risk (adjusted OR 4.76; 95% CI 2.67-8.47; P < 0.001). CONCLUSIONS: Guideline-conforming preoperative withdrawal of ticagrelor and clopidogrel was associated with a 50% reduced BARC-4 bleeding risk when corrected for EuroSCORE II and cardiopulmonary bypass time but was not associated with increased risk of 30-day mortality or postoperative ischaemic events.
引用
- Schoerghuber M, Kuenzer T, Biancari F, et al. Platelet inhibitor withdrawal and outcomes after coronary artery surgery: an individual patient data meta-analysis. Eur J Cardiothorac Surg. 2024. PMID: 38970368. doi:10.1093/ejcts/ezae265
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。